Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Prognosis following the initiation of various immune checkpoint inhibitor therapies in TTF-1-negative non-small cell lung cancer.

The hypothesis that CTLA-4 antibody-containing regimens may be effective for patients with TTF-1-negative non-squamous NSCLC is suggested, although the present study failed to identify the immune checkpoint inhibitor therapy associated with improved survival.

Minehiko Inomata, Yutaro Moriyasu, T. Tsuda et al. · 0 citations
Open access Oct 2026

Neutrophils and CSF1 promote the expansion of monocyte-derived alveolar macrophages in progressive pulmonary fibrosis.

Progressive pulmonary fibrosis (PPF) is a fatal lung condition characterized by persistent inflammation and progressive fibrotic remodeling. Monocyte-derived alveolar macrophages (Mo-AMs) are key drivers of fibrogenesis; however, the mechanisms underlying their persistence in fibrotic lungs remain unclear. Using lineag...

K. Kase, Satoshi Watanabe, Masafumi Horie et al. · 0 citations
Open access Aug 2026

Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis

Nivolumab plus ipilimumab-based therapies have shown long-term, durable clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC), including those with tumor programmed death-ligand 1 (PD-L1) expression < 1%, a population with high unmet need. Here we report long-term clinical outcomes with first-...

Makoto Nishio, H. Hayashi, Yasushi Goto et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.